Endocrine consequences of danazol treatment in menorrhagia
article
OA: bronze
CC0
⤵ 3 in-corpus citations
AI-generated summary
This study investigated the endocrine effects of danazol treatment in patients experiencing menorrhagia, analyzing hormonal changes and their impact on the condition.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
In order to study the endocrine side-effects of danazol, 15 patients with severe, benign menorrhagias, were individually treated with this drug to stop bleeding. LH, FSH, testosterone, free testosterone, DES-S, androstenedione, prolactin, estradiol and cortisol serum concentrations were measured before and after the 3 month treatment period. Danazol was found to be effective in reducing the amount of bleeding in patients with benign, severe menorrhagias; however, the weight gain of patients was significant during the 3 month period. LH and estradiol concentrations decreased; testosterone, free testosterone and dehydroepiandrosterone sulfate increased; prolactin, FSH, androstenedione and cortisol serum concentrations did not change, and SHBG disappeared from the serum, during the treatment period. We are of the opinion that danazol is an effective drug in menorrhagias with side-effects. In our view the hyperandrogenicity is the most important side-effect of this substance, which might be the result of some metabolites, but which might be the effect of a peripheral action of the drug as well.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (23)
- Changes in the shbg concentration during danazol treatment via openalex
- Competitive inhibition by Danazol of oestradiol binding to rabbit and ovine uterine oestradiol receptor via openalex
- Danazol: Endocrine consequences in healthy women via openalex
- Danazol—Introductory remarks via openalex
- Danazol treatment of severely symptomatic fibrocystic breast disease and long‐term follow‐up—the Hjørring project via openalex
- Effect of danazol on serum concentrations of pituitary gonadotropins in postmenopausal women via openalex
- EFFECT OF DANAZOL ON SERUM GONADOTROPHINS AND STEROID HORMONE CONCENTRATIONS IN WOMEN WITH MENORRHAGIA via openalex
- Effects of Danazol on Pituitary Gonadotrophins in Post‐Menopausal Women via openalex
- Endocrine effects of danazol in menstruating women. via openalex
- Endocrine effects of danazol in the treatment of endometriosis via openalex
- Inhibition of steroid sulfatase activity by danazol via openalex
- Radioimmunoassay for Danazol in Human and Monkey Plasma via openalex
- Regression of endometriosis following shorter treatment with, or lower dose of danazol: Comparison of pre‐ and post‐treatment laparoscopic findings in the Scandinavian multi‐center study via openalex
- The Effect of Danazol on Anterior Pituitary Function via openalex
- The effects of danazol on gonadotropins and steroid blood levels in normal and anovulatory women. via openalex
- The influence of danazol on pituitary function and on the ovarian follicular hormone secretion in premenopausal women via openalex
- W6698547173 via openalex
- doi:10.3109/00016348409156998 via openalex
- doi:10.1016/0006-8993(79)90068-4 via openalex
- doi:10.1016/0002-9378(81)90611-6 via openalex
- W2416009079 via openalex
- W2417927566 via openalex
- doi:10.3109/00016348409156996 via openalex
Cited by (3)
Source provenance
- openalex
- last seen: 2026-05-10T10:55:33.458592+00:00
License: CC0
· commercial use OK